Solid Dispersion Formulations of Megestrol Acetate with Copovidone for Enhanced Dissolution and Oral Bioavailability

다국어 초록 (Multilingual Abstract)

In order to enhance the dissolution profile and oral bioavailability of megestrol acetate (MA), solid dispersions of MA (MASDs) were formulated with copovidone and crystal sugar as a hydrophilic polymeric carrier and an inert core bead, respectively. Solvent evaporation method and fluidized bed coating technique were employed. MASDs were categorized as crystalline solid dispersion by the characterization of differential scanning calorimetry and X-ray diffraction. The mass-median diameters of MASDs were in a range of 1.4 to 2.6 μm. Based on drug to polymer ratio, MASD (1:1) and (1:2) were considered as optimized formulations, resulting in a smooth-surfaced homogeneously coated layer with enhanced dissolution rate. Dissolution of MASD was gradually increased up to 15 min, after which it reached a plateau. For the initial period, dissolution rates were in the decreasing order of MASD (1:2) ≥ MASD (1:1) > MASD (1:3) > MASD (1:5) > MASD (1:0.5) > MA powder. In the comparative pharmacokinetic study with Megace OS, a reference drug product, MASD (1:1) showed improved bioavailability of over 220% with 2-fold higher C_max and 30% faster T_max. We conclude that MASD (1:1) is a good candidate for the development of oral solid dosage forms.

참고문헌 (Reference)

1 Feliu, J., "Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study" 15 : 436-440, 1992

2 Al-Hamidi, H., "To enhance dissolution rate of poorly watersoluble drugs: Glucosamine hydrochloride as a potential carrier in solid dispersion formulations" 76 : 170-178, 2010

3 Carrier, R. L., "The utility of cyclodextrins for enhancing oral bioavailability" 123 : 78-99, 2007

4 Ho, H.-O., "The preparation and characterization of solid dispersions on pellets using a fluidized-bed system" 139 : 223-229, 1996

5 Bruera, E., "Symptomatic effects of megestrole acetate (MA): a double blind cross-over study (abstract)" 531-, 1996

6 Taylor, L. S., "Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions" 14 : 1691-1698, 1997

7 Simamora, P., "Solubilization of rapamycin" 213 : 25-29, 2001

8 Kawakami, K., "Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents" 28 : 7-14, 2006

9 Vasconcelos, T., "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs" 12 : 1068-1075, 2007

10 Bloch, D. W., "Solid dispersions - fundamentals and examples" 62 : 23-27, 1987

11 Serajuddin, A. T., "Solid dispersion of poorly water-soluble drug: early promises, subsequent problems, and recent breakthroughs" 88 : 1058-1066, 1999

12 Shah, N. H., "Self-emulsifying drug-delivery systems (SEDDS) with polyglycolyzed glycerides for improving invitro dissolution and oral absorption of lipophilic drugs" 106 : 15-23, 1994

13 Newa, M., "Preparation, characterization and in vivo evaluation of ibuprofen binarysolid dispersions with poloxamer 188" 343 : 228-237, 2007

14 Wang, L., "Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method" 54 : 37-43, 2006

15 Bühler, V., "Polyvinylpyrrolidone excipients for pharmaceuticals; Povidone, crospovidone and copovidone" Springer 2005

16 Bromberg, L., "Polymeric micelles in oral chemotherapy" 128 : 99-112, 2008

17 Barreiro-Iglesias, R., "Pluronic-gpoly( acrylic acid) copolymers as novel excipients for site specific, sustained release tablets" 26 : 374-385, 2005

18 J. Pharm. Pharmacol., "Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate" 56 : 1233-1241, 2004

19 Walsh, P., "Physicians’ desk reference" Medical Economics Co 2002

20 Zhang, X., "Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique" 182 : 480-485, 2008

21 Wang, X., "Phase characterization of indomethacin in binary solid dispersion with PVP VA64 or Myrj 52" 345 : 95-100, 2007

22 Loprinzi, C. L., "Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia" 11 : 762-767, 1993

23 Chiou, W. L., "Pharmaceutical applications of solid dispersion systems" 60 : 1281-1302, 1971

24 Singh, A. K., "Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS)" 10 : 906-916, 2009

25 Patel, D., "Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS)" 33 : 1318-1326, 2007

26 Kawabata, Y., "Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability" 39 : 256-262, 2010

27 Kesisoglou, F., "Nanosizing—oral formulation development and biopharmaceutical evaluation" 59 : 631-644, 2007

28 Merisko-Liversidge, E., "Nanosizing: a formulation approach for poorly-water-soluble compounds" 18 : 113-120, 2003

29 Rasenack, N., "Microcrystals for dissolution rate enhancement of poorly watersoluble drugs" 254 : 137-145, 2003

30 Tchekmedyian, N. S., "Megestrol acetate in cancer anorexia and weight loss" 69 : 1268-1274, 1992

31 Karavas, E., "Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions" 66 : 334-347, 2007

32 Li, F. -Q., "In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets" 324 : 152-157, 2006

33 Arida, A, I., "Improving the high variable bioavailability of griseofulvin by SEDDS" 55 : 1713-1719, 2007

34 Yeh, S. S., "Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double blind, placebocontrolled study" 48 : 485-492, 2000

35 Karatas, A., "Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol" 60 : 777-782, 2005

36 Won, D. H., "Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process" Elsevier BV 301 (301): 199-208, 2005

37 Pouton, C. W., "Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system" 29 : 278-287, 2006

38 Vippagunta, S. R., "Factors affecting the formation of eutectic solid dispersions and their dissolution behavior" 96 : 294-304, 2007

39 Chen, Y., "Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68" 286 : 69-80, 2004

40 Sant, V. P., "Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies" 104 : 289-300, 2005

41 Sun, N., "Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique" 182 : 72-80, 2008

42 Cho, E., "Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives" ELSEVIER SCIENCE BV 396 (396): 91-98, 2010

43 Hasegawa, S., "Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method" 302 : 103-112, 2005

44 Keck, C. M., "Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation" 62 : 3-16, 2006

45 Monnoyer, S., "Development of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of flurogestone acetate in ovine plasma" 819 : 245-251, 2005

46 Duchëne, D., "Cyclodextrins in targeting application to nanoparticles" 36 : 29-40, 1999

47 Brewster, M. E., "Cyclodextrins as pharmaceutical solubilizers" 59 : 645-666, 2007

48 Blagden, N., "Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates" 59 : 617-630, 2007

49 Yi, Y., "A mixed polymeric micelles formulation of itraconazole: Characteristics, toxicity and pharmacokinetics" 117 : 59-67, 2007